APA (7th ed.) Citation

Naing, A., Khalil, D., Thomas, M., Lillie, T., Rosen, O., Rosen, L., . . . Stacey, A. First-in-human clinical outcomes with NG-350A, an anti-CD40 expressing tumor-selective vector designed to remodel immunosuppressive tumor microenvironments. BMJ Publishing Group.

Chicago Style (17th ed.) Citation

Naing, Aung, Danny Khalil, Matthew Thomas, Tom Lillie, Oliver Rosen, Lee Rosen, D Ross Camidge, Rui-Ru Ji, and Andrea Stacey. First-in-human Clinical Outcomes with NG-350A, an Anti-CD40 Expressing Tumor-selective Vector Designed to Remodel Immunosuppressive Tumor Microenvironments. BMJ Publishing Group.

MLA (9th ed.) Citation

Naing, Aung, et al. First-in-human Clinical Outcomes with NG-350A, an Anti-CD40 Expressing Tumor-selective Vector Designed to Remodel Immunosuppressive Tumor Microenvironments. BMJ Publishing Group.